![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Salmeterol xinafoate, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2008-216 - Rev 01
This Chemical Type CEP, issued on September 25, 2017, remains in force until October 29, 2020, ensuring its reliability within the pharmaceutical industry.
Substance Number 1765 associated with this CEP further emphasizes